Catalyst Event

Celltrion Inc (068270) · Other

From Akros SCHK HK-Korea Low Volatility Factor Index (ASHKLVL)

4/23/2026, 12:00:00 AM

OtherSentiment: Positive

Celltrion announced that all three of its leading Antibody-Drug Conjugate (ADC) anti-cancer drug candidates (CT-P70, CT-P71, CT-P73) have entered the patient dosing stage in Phase 1 clinical trials; estimated 10% price impact due to significant pipeline expansion, expected.

Korean Translation

셀트리온, 항체·약물접합체(ADC) 항암 신약 후보물질 3종(CT-P70, CT-P71, CT-P73) 모두 임상 1상 환자 투약 단계에 진입하여 신약 파이프라인 개발이 본격화됨; 10% 주가 영향이 예상됨.

Related Recent Events

View Full Timeline